Literature DB >> 9525634

Viruses and cells with mutations affecting viral entry are selected during persistent rotavirus infections of MA104 cells.

J Z Mrukowicz1, J D Wetzel, M I Goral, A B Fogo, P F Wright, T S Dermody.   

Abstract

To better understand mechanisms of persistent rotavirus infections of cultured cells, we established independent, persistently infected cultures of MA104 cells, using rotavirus strain SA11. The cultures were either passaged when the cells reached confluence or supplemented with fresh medium every 7 days. Viral titers in culture lysates varied from 10(4) to 10(7) PFU per ml during 350 days of culture maintenance. Trypan blue staining indicated that 72 to 100% of cells in the cultures were viable, and immunocytochemical staining using a monoclonal antibody directed against viral protein VP6 demonstrated that 38 to 63% of the cells contained rotavirus antigen. We tested the capacity of rotaviruses isolated from the persistently infected cultures (PI viruses) to infect cells cured of persistent infection. Although wild-type (wt) and PI viruses produced equivalent yields in parental MA104 cells, PI viruses produced greater yields than wt virus in cured cells, which indicates that viruses and cells coevolve during persistent rotavirus infections of MA104 cells. To determine whether mutations in viruses and cells selected during these persistent infections affect viral entry, we tested the effect of trypsin treatment of the viral inoculum on growth of wt and PI viruses. Trypsin pretreatment is required for postattachment penetration of rotavirus virions into cells. In contrast to the case with wt virus, PI viruses produced equivalent yields with and without trypsin pretreatment in parental MA104 cells. However, PI viruses required trypsin pretreatment for efficient growth in cured cells. These results indicate that mutant viruses and cells are selected during maintenance of persistent rotavirus infections of MA104 cells and suggest that mutations in each affect trypsin-dependent steps in rotavirus entry.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525634      PMCID: PMC109759          DOI: 10.1128/JVI.72.4.3088-3097.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Identification and partial characterization of a rhesus rotavirus binding glycoprotein on murine enterocytes.

Authors:  D M Bass; E R Mackow; H B Greenberg
Journal:  Virology       Date:  1991-08       Impact factor: 3.616

2.  The VP8 fragment of VP4 is the rhesus rotavirus hemagglutinin.

Authors:  L Fiore; H B Greenberg; E R Mackow
Journal:  Virology       Date:  1991-04       Impact factor: 3.616

3.  Alteration of the pH dependence of coronavirus-induced cell fusion: effect of mutations in the spike glycoprotein.

Authors:  T M Gallagher; C Escarmis; M J Buchmeier
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

4.  Antibodies to the trypsin cleavage peptide VP8 neutralize rotavirus by inhibiting binding of virions to target cells in culture.

Authors:  F M Ruggeri; H B Greenberg
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

5.  Persistent infection of K562 cells by encephalomyocarditis virus.

Authors:  I U Pardoe; K K Grewal; M P Baldeh; J Hamid; A T Burness
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

6.  Rotavirus is released from the apical surface of cultured human intestinal cells through nonconventional vesicular transport that bypasses the Golgi apparatus.

Authors:  N Jourdan; M Maurice; D Delautier; A M Quero; A L Servin; G Trugnan
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

7.  Infectious rotavirus enters cells by direct cell membrane penetration, not by endocytosis.

Authors:  K T Kaljot; R D Shaw; D H Rubin; H B Greenberg
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

8.  Isolation and characterization of HeLa cell lines blocked at different steps in the poliovirus life cycle.

Authors:  G Kaplan; A Levy; V R Racaniello
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

9.  Localization of VP4 neutralization sites in rotavirus by three-dimensional cryo-electron microscopy.

Authors:  B V Prasad; J W Burns; E Marietta; M K Estes; W Chiu
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

10.  Phenotypes of rotavirus reassortants depend upon the recipient genetic background.

Authors:  D Chen; J W Burns; M K Estes; R F Ramig
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

View more
  5 in total

1.  Mutations in the rotavirus spike protein VP4 reduce trypsin sensitivity but not viral spread.

Authors:  Shane D Trask; J Denise Wetzel; Terence S Dermody; John T Patton
Journal:  J Gen Virol       Date:  2013-02-20       Impact factor: 3.891

2.  Virus-host coevolution in a persistently coxsackievirus B3-infected cardiomyocyte cell line.

Authors:  Sandra Pinkert; Karin Klingel; Vanessa Lindig; Andrea Dörner; Heinz Zeichhardt; O Brad Spiller; Henry Fechner
Journal:  J Virol       Date:  2011-10-05       Impact factor: 5.103

3.  Rapid selection in modified BHK-21 cells of a foot-and-mouth disease virus variant showing alterations in cell tropism.

Authors:  C Escarmís; E C Carrillo; M Ferrer; J F Arriaza; N Lopez; C Tami; N Verdaguer; E Domingo; M T Franze-Fernández
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

4.  Persistent hepatitis C virus infection in vitro: coevolution of virus and host.

Authors:  Jin Zhong; Pablo Gastaminza; Josan Chung; Zania Stamataki; Masanori Isogawa; Guofeng Cheng; Jane A McKeating; Francis V Chisari
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

5.  Dietary Lactobacillus rhamnosus GG Supplementation Improves the Mucosal Barrier Function in the Intestine of Weaned Piglets Challenged by Porcine Rotavirus.

Authors:  Xiangbing Mao; Changsong Gu; Haiyan Hu; Jun Tang; Daiwen Chen; Bing Yu; Jun He; Jie Yu; Junqiu Luo; Gang Tian
Journal:  PLoS One       Date:  2016-01-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.